A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER PHASE 2B/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF IZOKIBEP IN SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS
- Registry ID
- 22104
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE2
- Study type
- INTERVENTIONAL
- Sponsor
- ACELYRIN INC.
- Start date
- 2023-09-28
- Last update
- 2023-02-10
Conditions
- ACTIVE PSORIATIC ARTHRITIS
- PSORIATIC ARTHRITIS
Related clinical trials
- A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TULISOKIBART IN PARTICIPANTS WITH PSORIATIC ARTHRITIS
- A PHASE 2 MULTICENTER, RANDOMIZED, PLATFORM STUDY OF TARGETED THERAPIES FOR THE TREATMENT OF ADULT SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS
- A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, AND PLACEBO-CONTROLLED PHASE 3
STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ZASOCITINIB (TAK-279) IN SUBJECTS
WITH ACTIVE PSORIATIC ARTHRITIS STRATIFIED BY PRIOR BIOLOGIC USE (LATITUDE-PSA-
3002)
- A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF JNJ-77242113 FOR THE TREATMENT OF BIOLOGIC-EXPERIENCED AND BIOLOGIC-NAÏVE PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS
- A PHASE 3, PARALLEL-GROUP, RANDOMIZED, DOUBLE-BLIND, 4-ARM, PLACEBOCONTROLLED, MULTICENTER STUDY WITH RISANKIZUMAB AS ACTIVE REFERENCE ARM, TO
INVESTIGATE THE EFFICACY AND SAFETY OF SUBCUTANEOUS SONELOKIMAB IN MALE AND
FEMALE PARTICIPANTS AGED 18 YEARS AND OVER WITH ACTIVE PSORIATIC ARTHRITIS AND
PREVIOUS INADEQUATE RESPONSE OR INTOLERANCE TO TUMOR NECROSIS FACTOR-¿
INHIBITORS
- A PHASE 3, PARALLEL-GROUP, RANDOMIZED, DOUBLE-BLIND, 3-ARM, PLACEBOCONTROLLED, MULTICENTER STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF
SUBCUTANEOUS SONELOKIMAB IN MALE AND FEMALE PARTICIPANTS AGED 18 YEARS AND
OVER WITH ACTIVE PSORIATIC ARTHRITIS WHO ARE NAIVE TO BIOLOGIC DMARDS
View on source registry